Where is the manufacturer of Ixazomib?

Ixazomib citrate (Ixazomib), marketed by Takeda Pharmaceuticals under the trade name Ninlaro, is a prodrug that is rapidly converted to its active metabolite, ixazomib, upon administration. Ixazomib is the only oral proteasome inhibitor currently used to treat multiple myeloma. The active substance ixazomib blocks the proteasome, a system within cells that breaks down proteins when they are no longer needed.

When proteins in cancer cells, including proteins that control cell growth, are not broken down, the cancer cells become damaged and eventually die. Ixazomibis available in three different capsule dosages, namely4 mg, 3 mg and 2.3 mg. Patients can take Ixazomib orally; according to the drug batch For quasi-study studies, it should be taken once weekly on days 1, 8, and 15 of a 28-day cycle, with the recommended dose being 4 mg, which may be reduced to 3 mg in patients with moderate or severe hepatic impairment, renal impairment, or those requiring dialysis.

The original drug of Ixazomib has been launched in China and is included in Class B medical insurance. The price of common capsule preparations may be more than 10,000 yuan per box, which is relatively expensive. The price of the original drug of ixazomib sold overseas is more than 10,000 US dollars per box (the price may fluctuate due to the exchange rate). Ixazomib Generic drugs are also produced and sold overseas, and their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 4mg*3 tablets produced by a Laos pharmaceutical factory may be less than 1,000 yuan per box (the price may fluctuate due to the exchange rate), and the price is relatively cheap.